杨森生物品牌怎么样 申请店铺

我要投票 杨森生物在医疗器械行业中的票数:386 更新时间:2025-08-12
杨森生物是哪个国家的品牌?「杨森生物」是 武汉杨森生物技术有限公司 旗下著名品牌。该品牌发源于湖北省武汉市,由创始人靳苗在2009-04-28期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力杨森生物品牌出海!将品牌入驻外推网,定制杨森生物品牌推广信息,可以显著提高杨森生物产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

杨森生物怎么样

武汉杨森生物技术有限公司是一家从事医疗器械研发和代理的企业,成立于2009年4月,公司位于湖北省武汉国家生物产业基地。企业始终坚持以自主创新为主,企业结构和规模得到迅速的发展和壮大。  

公司从2009年50万的注册资金,到现在已有注册资产779.22万;拥有1000m2GMP认证的生产厂房,200m2 办公楼;目前已拥有3项发明专利和1项实用新型,3项发明专利和1项PCT专利已受理,公司设置3个职能部门,包括研发部门、管理部门和销售部门;现有员工30余人,其中博士硕士以上学历者占总人数的83%,体现企业自主研发特色。

杨森公司所研制的三层仿生小口径人造血管项目是以人体自身的小动脉的结构作为参照的人造血管。与以前普遍采用纯纤维材料(涤纶织物或蚕丝)或某种高分子材料(ePTFE)单一组成的人造血管相比,本项目创造性地设计出具有三层结构的更接近于人体血管结构和功能的复合人造血管。该人造血管不仅模拟人体小动脉血管的三层解剖结构(单层上皮细胞构成的血管内膜、富含弹力的平滑肌纤维构成的中层和结缔组织构成的外层),而且还模拟每层结构的功能,内层采用聚氨酯与非水溶性丝素粉体相结合模拟内皮及其少量结缔组织,中间层采用纺织材料制成的管状弹性织物来模拟人体血管中的富含弹性的平滑肌纤维层,外层采用聚氨酯与非水溶性丝素粉体来模拟结缔组织;同时沿厚度方向由内向外实现梯度多孔,模拟血管壁的微孔结构。  

核心发明专利:一种织物增强的复合人造血管,专利号:200610166568。 该项目已于2014年完成该项目的生产许可认证,2014年底将样品递交至第三方机构进行形式审核,预计2015年完成该第三方检测工作并提交至国家药监局进行临床申报工作,2016年-2018年完成该项目的临床试验,2018年中旬获取该项目的注册批件并在国内进行上市销售。在此期间,力争同时完成欧盟的CE认证与通过FDA510K证书,从而打开产品的国际市场。  

公司的人造血管项目已获得专利,目前该人造血管在动物实验中已取得重大突破,正处于投产阶段,这将是较符合人体生理结构的人造血管。一旦产品成功上市,将推动该领域民族工业的发展,对中国生物医用材料的发展也具有重要的经济价值和社会价值。


Wuhan YANGSEN Biotechnology Co., Ltd. is an enterprise engaged in R & D and agency of medical devices, established in April 2009, located in Wuhan National biological industry base, Hubei Province. Enterprises always adhere to the principle of independent innovation, and their structure and scale have been rapidly developed and expanded. The company has registered capital of RMB 500000 in 2009, and now has registered assets of RMB 7792200; it has 1000m2gmp certified production plant and 200m2 office building; at present, it has 3 invention patents and 1 utility model, 3 invention patents and 1 PCT patent have been accepted, and the company has set up 3 functional departments, including R & D department, management department and sales department; it has more than 30 employees, including Bo Bo Scholars with master's degree or above account for 83% of the total number, reflecting the independent R & D characteristics of the enterprise. The three-layer bionic small caliber artificial blood vessel project developed by Janssen company is an artificial blood vessel with reference to the structure of human own small artery. Compared with the artificial blood vessel made of pure fiber material (polyester fabric or silk) or a kind of polymer material (ePTFE), this project creatively designs a composite artificial blood vessel with three-layer structure, which is closer to the structure and function of human blood vessel. The vascular prosthesis not only simulates the three-layer anatomical structure of human arterioles (the vascular intima composed of monolayer epithelial cells, the middle layer composed of elastic smooth muscle fibers and the outer layer composed of connective tissue), but also simulates the function of each layer structure. The inner layer uses polyurethane combined with insoluble silk powder to simulate the endothelium and a small amount of connective tissue, and the middle layer uses spinning The tubular elastic fabric is made of the fabric material to simulate the elastic smooth muscle fiber layer in human blood vessels, and the outer layer is polyurethane and insoluble silk fibroin powder to simulate the connective tissue; at the same time, the gradient porous is realized from the inside to the outside along the thickness direction to simulate the microporous structure of the blood vessel wall. Core invention patent: a fabric reinforced composite artificial blood vessel, patent No.: 200610166568. The project has completed the production license certification of the project in 2014. At the end of 2014, the samples will be submitted to a third-party organization for formal review. It is expected that the third-party testing will be completed in 2015 and submitted to the State Food and Drug Administration for clinical application. The clinical trials of the project will be completed in 2016-2018. In the middle of 2018, the project's registration approval will be obtained and listed in China. During this period, strive to complete the CE certification of EU and pass the fda510k certificate at the same time, so as to open the international market of products. The company's artificial blood vessel project has been patented. At present, the artificial blood vessel has made a major breakthrough in animal experiments and is in the production stage, which will be more in line with human physiological structure. Once the product is successfully listed, it will promote the development of national industry in this field, and also has important economic and social value for the development of biomedical materials in China.

本文链接: https://brand.waitui.com/6bfa48b93.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

巴西称美方取消两国财长视频会议

当地时间8月11日,巴西财政部长哈达德透露,原定13日与美国财政部长贝森特就巴西产品关税问题举行的视频会议已被美方取消,目前新的会议日期尚未确定。哈达德在接受采访时表示,巴西政府计划为巴西企业推出融资、公共采购和税务分析三项临时举措,以应对美加征关税影响。(央视新闻)

2小时前

科技创新债发行扩容,热度有望延续

今年5月,中国人民银行、中国证监会联合发布关于支持发行科技创新债券有关事宜的公告。公告发布后,科技创新债市场快速扩容,发行只数、发行规模较去年同期激增,政策落地效果显著。专家表示,科技创新债有望迎来更多供给,还需从推动债券条款创新、丰富增信措施等方面入手,提升投资者对民营企业科技创新债的认可度,提高发债成功率。(中证报)

2小时前

券商年内已宣布撤销87家分支机构

近年来,随着投资者的业务办理逐渐向线上转移,叠加降本增效目标的驱动,券商密集对旗下营业部、子公司等分支机构进行撤销或合并,以优化资源配置。据统计,截至8月11日,年内券商已宣布撤销87家分支机构。“券商对线下分支机构进行整合、精简,是节约经营成本、提升展业效率的要求,也是互联网时代行业发展的必然趋势。”盘古智库(北京)信息咨询有限公司高级研究员余丰慧表示。(证券日报)

2小时前

华泰证券:建议关注新疆板块投资机会

36氪获悉,华泰证券研报认为,近日国家铁路集团注册资本950亿元成立新藏铁路公司,新藏铁路建设预计对应总投资2000亿元—5000亿元,和田至省界段已于2025年5月启动土石方招投标,此次专业公司成立标志项目稳步推进。华泰证券认为新疆在能源、资源、地缘优势下战略地位突出,政策高度重视区域发展,随着疆内产业发展、重大基建落地,有望迎来加速发展。同时短期自治区成立70周年或继续成为市场重要催化之一,建议关注新疆板块投资机会。

2小时前

2025年并购重组市场明显提速,呈现四大新特征

2025年以来,并购重组市场明显提速,涉及公司数量显著增加。从大背景来看,无论是政策端的大力推动,还是市场主体的积极参与,都使得并购重组愈发活跃。数据显示,本轮并购重组浪潮呈现四大特征:规模更大、双创公司占比高、政策包容性更强、聚焦产业整合。这些新特征有望对各个行业的竞争格局进行重塑,并为经济的高质量发展注入全新活力。(证券时报)

2小时前

本页详细列出关于杨森生物的品牌信息,含品牌所属公司介绍,杨森生物所处行业的品牌地位及优势。
咨询